Lipella announces 1-for-8 reverse split effective Nov 7 to meet Nasdaq bid price

LIPELLA PHARMACEUTICALS INC.

Reverse stock split ratio of 1-for-8; effective 5:00 p.m. ET on November 7, 2024.
Common stock begins trading split-adjusted on November 8, 2024 under symbol LIPO.
Authorized shares unchanged at 200,000,000; par value remains $0.0001 per share.
Split intended to bring company into compliance with Nasdaq minimum bid price requirement.
Approved by stockholders at Annual Meeting on September 10, 2024; CUSIP changes to 53630L209.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.